FORMULATION ARTICLES
-
![RNA, siRNA, mRNA, CRISPR-GettyImages-1409578455]( "Scaling RNA Therapeutics: Purification, LNP Formulation, And GMP Manufacturing (Pt. 2)")
Scaling RNA Therapeutics: Purification, LNP Formulation, And GMP Manufacturing (Pt. 2)Part 2 explores the downstream technologies that turn RNA into a therapeutic product, from impurity removal and LNP formulation to GMP infrastructure and scalable manufacturing.
-
![NeurExone_coverphoto]( "From Exosomes To Nanodrugs: Advancing Therapeutic Delivery For CNS Repair")
From Exosomes To Nanodrugs: Advancing Therapeutic Delivery For CNS RepairExosomes are biological vesicles used for cellular communication that can overcome CNS barriers, delivering therapeutic cargo for CNS and optic nerve injuries.
-
![GettyImages-1447956737]( "Why RNAi-Based Oncology Must Move Beyond Single-Target Thinking")
Why RNAi-Based Oncology Must Move Beyond Single-Target ThinkingRNAi therapeutics may help oncology move beyond single-target drugs by disrupting adaptive tumor survival networks driving resistance in solid tumors.
-
![Green Business-GettyImages-2179499504]( "What Makes An RNA Platform Investable? Lessons From The Last Wave Of Biotech Financing")
What Makes An RNA Platform Investable? Lessons From The Last Wave Of Biotech FinancingRNA investing has shifted from hype to scalability, forcing companies to prove manufacturability, delivery strength, and platform-wide value.
-
![Ribosome, biological cell constructing mRNA molecule-GettyImages-1352440366]( "Beyond Hairpins: A New Translational Repression Assay Expands RNA-Binding Protein Research")
Beyond Hairpins: A New Translational Repression Assay Expands RNA-Binding Protein ResearchResearchers expanded translational repression assays beyond RNA hairpins, enabling scalable study of linear RNA-protein interactions in living cells.
-
![Molecular biology, mRNA strands, genetics-GettyImages-2198118160]( "Engineering RNA Payload Distribution In LNPs To Unlock Higher In Vivo Gene Editing Efficiency")
Engineering RNA Payload Distribution In LNPs To Unlock Higher In Vivo Gene Editing EfficiencyNew research shows RNA payload distribution inside LNPs — not just encapsulation efficiency — may be key to unlocking stronger in vivo gene editing performance.
FORMULATION VIDEOS
Learn a validated, end-to-end protocol for producing high-quality in vitro transcription (IVT) mRNA for preclinical research. Find out how to optimize sequence design, small-scale synthesis, and more.
Develop RNA-lipid nanoparticles (LNPs) in under 10 seconds for drug discovery and early preclinical development. The NanoAssemblr®️ Spark™ instrument enables rapid µL formulations to conserve limited and expensive ingredients with minimal waste.
Three LNP experts from Sanofi, Hopewell Therapeutics, and BioNTech collectively discuss how far we’ve come in understanding the structure of our LNPs while also shedding light on the variables that have the greatest potential of causing shifts in our products’ structure/function.
In this Advancing RNA Live clip, NanoVation’s Dominik Witzigmann and Stealth Co’s John Zuris break down the scientific advancements we’re seeing for each of an LNP’s components (i.e., the ionizable lipid, helper lipid, and PEG), albeit with the caveat that, with these advancements, Freedom to Operate (FTO) continues to grow increasingly complicated.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![iStock-1295693740-covid-coronavirus-vaccine-mrna]( "Developing A Scalable RNA-LNP Drug Product For Clinical Translation")
Accelerate essential process development activities with instrumentation solution allowing for highly reproducible and scalable production of RNA-LNPs.
-
![Lipid Nanoparticles GettyImages-1437855772]( "Advancing RNA-LNP Therapeutics As An Alternative To Viral Vectors")
RNA-LNP therapeutics offer a flexible, transient alternative to traditional viral vectors for genetic medicine. Learn about the advantages of LNPs in safety, scalability, and payload versatility.
-
![Lipid Nanoparticle mRNA Vaccine GettyImages-1418152448]( "Lowering The Lipid Barrier To RNA-LNP Therapeutics")
Industry experts discuss current and future trends, formulating successful lipid compositions and navigating the constantly evolving genomic medicine landscape.
-
![mRNA GettyImages-1356994723]( "The Future Of mRNA: Four Key Focuses For Industry")
Compared to traditional protein-based therapies, mRNA drugs exhibit unique pharmacokinetic profiles and can be rapidly developed, making overcoming their challenges critical for the industry.
-
![GettyImages-96310150-microfluidics.jpg]( "Getting Genomic Medicines Ready For Prime Time")
Explore the benefits of building a manufacturing process early, how research into LNPs in nucleic acid therapeutics will contribute to the development of future drugs, and more.
-
![Cleanroom Scientists Using Tablet GettyImages-1341292153]( "High-Throughput Platform Propels Gene Editing Therapy Research")
Explore the potential of polymeric nanoparticles (PNPs) as an alternative to viral vectors. PNPs offer design flexibility, enabling larger payloads, targeted release, and minimized side effects.
-
![Lipid Nanoparticle mRNA Vaccine GettyImages-1418152448]( "Trends In Next-Generation Delivery Technologies")
Learn how lipid nanoparticles are enabling a new generation of engineered cell therapies with a push toward more complex cell engineering and gene editing for allogeneic therapies.
